ArticleTranslational cancer research2023

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.

Yafei Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.